The best-laid plans

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 8, 2013, Pages 1086-1087

  Harris, Raymond C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BARDOXOLONE; BARDOXOLONE METHYL; KELCH LIKE ECH ASSOCIATED PROTEIN 1; RAMIPRIL; RTA 401; RTA 405; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ALBUMINURIA; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; EARLY TERMINATION OF CLINICAL TRIAL; EDITORIAL; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GRANULOMATOSIS; HUMAN; KIDNEY TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; PSEUDOTUMOR; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 84878646362     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00693.2012     Document Type: Editorial

References (8)

1. Giacco F, Brownlee M. Oxidative stress and diabetic complication. Circ Res 107: 1058-1070, 2010.
2. Ichikawa T, Li J, Meyer CJ, Janicki JS, Hannink M, Cui T. Dihydro-CDDO570 trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes. PLoS One 4: e8391, 2009.
3. Osburn WO, Yates MS, Dolan PD, Chen S, Liby KT, Sporn MB, Taguchi K, Yamamoto M, Kensler TW. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol Sci 104: 218-227, 2008.
4. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336, 2011.
5. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 74: 537-545, 2011.
6. Wu QQ, Wang Y, Senitko M, Meyer C, Wigley WC, Ferguson DA, Grossman E, Chen J, Zhou XJ, Hartono J, Winterberg P, Chen B, Agarwal A, Lu CY. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPAR-y, and HO-1. Am J Physiol Renal Physiol 300: F1180-F1192, 2011.
7. Zheng H, Whitman SA, Wu W, Wondrak Gt Wong PK, Fang D, Zhang DD. Therapeutic potential of Nrf2 activators in streptoxotocin-induced diabetic nephropathy. Diabetes 60: 3055-3066, 2011.
8. Zoja C, Corna D, Nava V, Locatelli M, Abbate M, Gaspari F, Carrara F, Sangalli F, Remuzzi G, Benigni A. Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol (First published November 7, 2012). doi:10.1152/ ajprenal.00376.2012.